Skip to main content
. 2015 Dec 31;10(12):e0145394. doi: 10.1371/journal.pone.0145394

Fig 2. Profile of genetic mutations and aberrant methylation.

Fig 2

(A) Mutation status of RAS pathway genes and secondary genes (SETBP1 and JAK3) identified as gene targets. Aberrant methylation scores (AMS) in a cohort of 92 patients with juvenile myelomonocytic leukemia are summarized. A rhombus denotes a patient with Noonan syndrome-associated myeloproliferative disorder. (B) Mutations in SETBP1 and JAK3 were associated with a higher AMS. The mean AMS of patients with SETBP1 and/or JAK3 mutations was higher than that of patients without secondary mutations (p = 0.03).